A9542 HCPCS Level II code: Indium in-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries

A9542 is the HCPCS code for “Indium in-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

A9542

Indium in-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries

Short description: In111 ibritumomab, dx

HCPCS · United States

Medicare details

The indicators CMS publishes with A9542 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Carrier judgment
Medicare pricing
Drugs
ASC
Approved for ambulatory surgical centers
Type of service
Diagnostic radiology
BETOS category
Standard imaging - nuclear medicine
Added
Jan 1, 2006

Where A9542 sits

  1. 1A codesAmbulance, supplies and miscellaneous
  2. 2Active code A9542Indium in-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code A9542 mean?

A9542 is the HCPCS code for “Indium in-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover A9542?

CMS lists A9542’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.